Cassava Sciences (NASDAQ:FLNA – Get Free Report) and BioVie (NASDAQ:BIVI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Earnings and Valuation
This table compares Cassava Sciences and BioVie”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.74 |
| BioVie | N/A | N/A | -$17.54 million | ($3.25) | -0.42 |
Profitability
This table compares Cassava Sciences and BioVie’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cassava Sciences | N/A | -53.90% | -34.20% |
| BioVie | N/A | -101.15% | -90.18% |
Volatility & Risk
Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Insider and Institutional Ownership
38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Cassava Sciences and BioVie, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cassava Sciences | 1 | 0 | 0 | 0 | 1.00 |
| BioVie | 1 | 0 | 0 | 0 | 1.00 |
Summary
Cassava Sciences beats BioVie on 5 of the 8 factors compared between the two stocks.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
About BioVie
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
